Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - December 12, 2025 184 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the DESTINY-Breast05 study Source RELATED ARTICLESMORE FROM AUTHOR Solid Organ Transplant Recipients with Pretransplant Cancer Have an Elevated Risk of Posttransplant Cancer of the Same Cancer Type Population-based lung cancer screening can reduce mortality in people who have never smoked, study shows in China EMA Recommends Granting a Conditional Marketing Authorisation for Tovorafenib MOST POPULAR Trial Establishes Preferred Treatment for Some People with Esophageal Cancer July 9, 2024 Genomic and Immunophenotypic Heterogeneity of Acquired Resistance to Immune Checkpoint Inhibitors... January 30, 2024 Utility of Prospective ctDNA Surveillance in Early TNBC and the Activity... December 5, 2022 Celebrating 75 years of NHS cancer care July 5, 2023 Load more HOT NEWS Forging Military Partnerships to Empower the Cancer Research Enterprise Patritumab Deruxtecan Demonstrates a Manageable Safety Profile and Durable Efficacy in... Representation, retention and hope – how a mentorship scheme is helping... 20.° Aniversario de Cancer.Net: Celebramos Nuestra Misión de Brindar Información Confiable...
